<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333082</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00538; me20Sutter</org_study_id>
    <nct_id>NCT04333082</nct_id>
  </id_info>
  <brief_title>Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction</brief_title>
  <acronym>RESET</acronym>
  <official_title>Refractory Status Epilepticus Treatment (RESET): Quality and Efficacy of Coma Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the effects of different treatment characteristics regarding the
      use of intravenous anesthetic drugs (IVADs) as a rescue treatment for refractory Status
      epilepticus (RSE) on course and outcome. A retrospective data extraction from the digital
      medical records, the electroencephalographic and microbiologic database of all consecutive
      adult patients with Status epilepticus (SE) admitted to the University Hospital Basel is
      undertaken.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of in- hospital death</measure>
    <time_frame>at baseline (T0)</time_frame>
    <description>number of in- hospital death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neurofunctional alteration assessed by Glasgow Outcome Score (GOS)</measure>
    <time_frame>at baseline (T0)</time_frame>
    <description>neurofunctional alteration assessed by Glasgow Outcome Score (GOS). The Glasgow Outcome Scale (GOS) is a global scale for functional outcome that rates patient status into one of five categories: Dead, Vegetative State, Severe Disability, Moderate Disability or Good Recovery</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Status Epilepticus</condition>
  <condition>Refractory Status Epilepticus</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>collection of patient data
Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (i.e., patients ≥18 years of age) with diagnosed SE between 2005 and 2019
        who have been treated at intensive care units (ICUs) of the University Hospital of Basel, a
        Swiss tertiary academic medical care center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed SE between 2005 and 2019 who have been treated at intensive care units
             (ICUs) of the University Hospital of Basel

        Exclusion Criteria:

          -  Patients with repetitive epileptic seizures not qualifying for SE or RSE

          -  Patients with documented refusal of the general in-house consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raoul Sutter, PD Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsspital Basel / Intensivmedizin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raoul Sutter, PD Dr. med</last_name>
    <phone>0041 61 328 7928</phone>
    <email>raoul.sutter@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anja Rybitschka, Cand. med.</last_name>
    <email>anja.rybitschka@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic for Intensive Care Medicine, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoul Sutter, PD Dr. med</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>raoul.sutter@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Anja Rybitschka, Cand. med.</last_name>
      <email>anja.rybitschka@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anja Rybitschka, Cand. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saskia Semmlack, Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>artificial deep coma</keyword>
  <keyword>intravenous anesthetic drugs (IVADs)</keyword>
  <keyword>total seizure oppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

